PD-L1 high expression (TPS >= 50%)
Gene: CD274 · Type: expression
Indications: Non-small cell lung cancer, Cervical cancer
Linked CIViC Profile: PDL1 EXPRESSION
Evidence Level Distribution
Level B: 21
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Prognostic | Does Not Support | Poor Outcome | Lung Non-small Cell Carcinoma | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Pembrolizumab,Nivolumab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Pembrolizumab,Nivolumab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Atezolizumab,Pembrolizumab,Avelumab,Nivolumab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Atezolizumab | 4 |
| B | Predictive | Supports | Resistance | Head And Neck Squamous Cell Carcinoma | Radiation Therapy | 4 |
| B | Prognostic | Supports | Poor Outcome | Cancer | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Pembrolizumab | 4 |
| B | Prognostic | Supports | Better Outcome | Lung Squamous Cell Carcinoma | 3 | |
| B | Prognostic | Supports | Better Outcome | Ovarian Serous Carcinoma | 3 | |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 3 | |
| B | Prognostic | Supports | Better Outcome | Stomach Carcinoma | 3 | |
| B | Predictive | Does Not Support | Sensitivity/Response | Melanoma | Ipilimumab,Nivolumab | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Pembrolizumab | 3 |
| B | Prognostic | Supports | Poor Outcome | Breast Cancer | 3 | |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Atezolizumab,Pembrolizumab,Nivolumab,Durvalumab,Avelumab | 3 |
| B | Prognostic | Supports | Poor Outcome | Lung Non-small Cell Carcinoma | 2 | |
| B | Predictive | Supports | Sensitivity/Response | Cancer | Nivolumab | 2 |
| B | Predictive | Does Not Support | Sensitivity/Response | Merkel Cell Carcinoma | Pembrolizumab | 2 |
| B | Prognostic | Supports | Poor Outcome | Breast Cancer | 2 |